Cardiol Therapeutics (CRDL) Price & Analysis

Compare

174 Followers

CRDL Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.09 - C$3.57

Previous CloseN/A

Volume34.34K

Average Volume (3M)108.84K

Market Cap

C$152.90M

Enterprise ValueC$120.88M

Total Cash (Recent Filing)C$23.29M

Total Debt (Recent Filing)C$150.66K

Price to Earnings (P/E)―

Beta1.89

Next Earnings

Aug 18, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding82,649,730

10 Day Avg. Volume153,038

30 Day Avg. Volume108,844

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$12.37

Price Target Upside568.41% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Revenue OpportunitySuccess in the ARCHER trial could offer a $500M revenue opportunity and leverage the data into broader cardiovascular indications.

Strategic PartnershipsShould CardiolRx read out positive results in the ARCHER trial for acute myocarditis, it could drive strategic interest from potential partners, not only for the myocarditis indication, but also for CRD-38 in heart failure.

Trial ResultsThe announcement that the database has been locked and topline results are expected soon is a meaningful positive, removing uncertainty about the timing of the ARCHER trial results.

Bears Say

Competition And Market ChallengesCurrently, there are no FDA-approved therapies for myocarditis.

Trial Execution RisksThe company is currently enrolling patients in the Phase III MAVERICK study in patients with recurrent pericarditis.

Cardiol Therapeutics News

Roth bullish on Cardiol, says trial results enough to attract larger partner

Keeping a Buy rating on Cardiol Therapeutics (CRDL), Roth Capital notes that top-line results for the ARCHER for...

2d ago

CRDL

Cardiol ARCHER study not statistically significant, says Canaccord

Canaccord says that while the top-line results from Cardiol Therapeutics (CRDL)’ Phase II ARCHER trial in patients with...

2d ago

CRDL

Cardiol falls 14% to $1.16 after myocarditis study results

10:08 EDT Cardiol falls 14% to $1.16 after myocarditis study results Published first on TheFly – the ultimate...

2d ago

CRDL

Cardiol data readout positive and not priced in, says H.C. Wainwright

H.C. Wainwright views the results from ardiol Therapeutics’ Phase II ARCHER trial of CardiolRx in acute myocarditis as...

2d ago

CRDL

Cardiol Therapeutics announces Phase II ARCHER results in myocarditis

Cardiol Therapeutics (CRDL) announced topline results from ARCHER, the company’s Phase II clinical trial in patients with acute...

2d ago

CRDL

Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements

Cardiol Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward Nash from...

2d ago

CRDL

Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis

An update from Cardiol Therapeutics ( ($TSE:CRDL) ) is now available. Cardiol Therapeutics announced positive topline results from...

2d ago

CRDL

Positive Outlook for Cardiol Therapeutics Amid ARCHER Trial Progress and Market Potential

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Cardiol Therapeutics today and set a price target...

17d ago

CRDL

Cardiol Therapeutics Achieves Database Lock in ARCHER Trial for Acute Myocarditis

Cardiol Therapeutics ( ($TSE:CRDL) ) has issued an update. On July 22, 2025, Cardiol Therapeutics announced the database...

17d ago

CRDL

Buy Rating for Cardiol Therapeutics: Promising Innovations in Heart Disease Treatment with CardiolRx and CRD-38

Brandon Folkes, an analyst from Rodman & Renshaw, has initiated a new Buy rating on Cardiol Therapeutics (CRDL)....

2M ago

CRDL

Cardiol Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $9 price target Cardiol is...

2M ago

CRDL

Cardiol Therapeutics Announces AGM Results and New Board Member

An announcement from Cardiol Therapeutics ( ($TSE:CRDL) ) is now available. On May 28, 2025, Cardiol Therapeutics held...

2M ago

CRDL

Cardiol Therapeutics Reports Q1 2025 Financial Results

Cardiol Therapeutics Inc. ( ($CRDL) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

CRDL

Cardiol Therapeutics to Webcast AGM Amidst Ongoing Clinical Trials

The latest update is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics announced that its virtual Annual...

2M ago

CRDL

CRDL FAQ

What was Cardiol Therapeutics Inc.’s price range in the past 12 months?

Cardiol Therapeutics Inc. lowest stock price was C$1.09 and its highest was C$3.57 in the past 12 months.

What is Cardiol Therapeutics Inc.’s market cap?

Cardiol Therapeutics Inc.’s market cap is C$152.90M.

When is Cardiol Therapeutics Inc.’s upcoming earnings report date?

Cardiol Therapeutics Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 10 days.

How were Cardiol Therapeutics Inc.’s earnings last quarter?

Cardiol Therapeutics Inc. released its earnings results on May 14, 2025. The company reported -C$0.1 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.1.

Is Cardiol Therapeutics Inc. overvalued?

According to Wall Street analysts Cardiol Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiol Therapeutics Inc. pay dividends?

Cardiol Therapeutics Inc. does not currently pay dividends.

What is Cardiol Therapeutics Inc.’s EPS estimate?

Cardiol Therapeutics Inc.’s EPS estimate is -0.14.

How many shares outstanding does Cardiol Therapeutics Inc. have?

Cardiol Therapeutics Inc. has 82,649,730 shares outstanding.

What happened to Cardiol Therapeutics Inc.’s price movement after its last earnings report?

Cardiol Therapeutics Inc. reported an EPS of -C$0.1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.258%.

Which hedge fund is a major shareholder of Cardiol Therapeutics Inc.?

Currently, no hedge funds are holding shares in TSE:CRDL

Cardiol Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-190.61%

Trailing 12-Months

Asset Growth

-23.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cardiol Therapeutics Inc.

Cardiol Therapeutics (CRDL) is a clinical-stage biotechnology company focused on the research and development of innovative anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases. The company operates primarily in the biopharmaceutical sector and is dedicated to advancing its proprietary cannabidiol-based formulations for heart failure and acute myocarditis, aiming to address unmet medical needs in these areas.

Cardiol Therapeutics (CRDL) Earnings & Revenues

Historic Earnings Reports

CRDL Stock 12 Month Forecast

Average Price Target

C$12.37

▲(568.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","7":"C$7","14":"C$14","3.5":"C$3.5","10.5":"C$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.7395476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$13.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.36559284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$12.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.99163808,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$10.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.8199652,3.7299303999999998,4.6398956,5.5498608,6.4598260000000005,7.3697912,8.2797564,9.1897216,10.0996868,11.009652,11.919617200000001,12.8295824,{"y":13.7395476,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.714276372307692,3.518552744615384,4.322829116923077,5.127105489230769,5.931381861538461,6.735658233846154,7.539934606153846,8.344210978461538,9.14848735076923,9.952763723076922,10.757040095384614,11.561316467692308,{"y":12.36559284,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.6085875446153843,3.307175089230769,4.005762633846153,4.704350178461538,5.402937723076922,6.101525267692307,6.800112812307692,7.498700356923076,8.197287901538461,8.895875446153845,9.59446299076923,10.293050535384614,{"y":10.99163808,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.84,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.605,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.695,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >